Literature DB >> 4569675

9 -Tetrahydrocannabinol in depressed patients.

J Kotin, R M Post, F K Goodwin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4569675     DOI: 10.1001/archpsyc.1973.01750330041007

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


× No keyword cloud information.
  7 in total

1.  Inactivity of delta9-tetrahydrocannabinol in antidepressant screening tests.

Authors:  R D Sofia; R K Kubena; H Barry
Journal:  Psychopharmacologia       Date:  1973-07-17

2.  Measuring Disturbance of the Endocannabinoid System in Psychosis: A Systematic Review and Meta-analysis.

Authors:  Amedeo Minichino; Morwenna Senior; Natascia Brondino; Sam H Zhang; Beata R Godwlewska; Philip W J Burnet; Andrea Cipriani; Belinda R Lennox
Journal:  JAMA Psychiatry       Date:  2019-09-01       Impact factor: 21.596

3.  Role of endocannabinoid signaling in anxiety and depression.

Authors:  Sachin Patel; Cecilia J Hillard
Journal:  Curr Top Behav Neurosci       Date:  2009

Review 4.  Endocannabinoid signaling in the etiology and treatment of major depressive illness.

Authors:  Cecilia J Hillard; Qing-song Liu
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

5.  Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.

Authors:  Corneliu N Stanciu; Mary F Brunette; Nikhil Teja; Alan J Budney
Journal:  Psychiatr Serv       Date:  2021-02-03       Impact factor: 3.084

6.  The Effectiveness of Cannabis Flower for Immediate Relief from Symptoms of Depression.

Authors:  Xiaoxue Li; Jegason P Diviant; Sarah S Stith; Franco Brockelman; Keenan Keeling; Branden Hall; Jacob M Vigil
Journal:  Yale J Biol Med       Date:  2020-06-29

7.  Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders.

Authors:  Christopher Noel
Journal:  Ment Health Clin       Date:  2018-03-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.